YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction

European Journal of Pharmacology

Volumn 549, Issue 1-3, 2006, Pages 185-191

  Nakano, Ryosuke ^a   Kurosaki, Eiji ^a   Shimaya, Akiyoshi ^a   Kajikawa, Satoru ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Diabetic nephropathy; Hyperlipidemia; Insulin resistance; Peroxisome proliferator activated receptor ; YM440; Zucker fatty rat

Indexed keywords

1,4 BIS[4 [(3,5 DIOXO 1,2,4 OXADIAZOLIDIN 2 YL)METHYL]PHENOXY]BUT 2 ENE; ALBUMIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CHOLESTEROL; DRUG VEHICLE; N ACETYL BETA GLUCOSAMINIDASE; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; YM 440;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CHOLESTEROL BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; ENZYMURIA; GLOMERULUS; HISTOLOGY; HYPERLIPIDEMIA; HYPOLIPEMIA; KIDNEY INJURY; KIDNEY TUBULE DISORDER; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARAMETERS OF MEASUREMENT AND ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RAT; RAT STRAIN; REGRESSION ANALYSIS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

ACETYLGLUCOSAMINIDASE; ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD UREA NITROGEN; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY; KIDNEY FUNCTION TESTS; MALE; OBESITY; ORGAN SIZE; OXADIAZOLES; RATS; RATS, ZUCKER; TRIGLYCERIDES;

EID: 33748954586     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.032     Document Type: Article

References (32)

1. Adeli K., Taghibiglou C., Van Iderstine S.C., and Lewis G.F. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc. Med. 11 (2001) 170-176
2. Bauer W.C., and Rosenberg B.F. A quantitative study of glomerular enlargement in children with tetralogy of Fallot. A condition of glomerular enlargement without an increase in renal mass. Am. J. Pathol. 37 (1960) 695-712
3. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 137 (1996) 354-366
4. Buckingham R.E., Al-Barazanji K.A., Toseland C.D., Slaughter M., Connor S.C., West A., Bond B., Turner N.C., and Clapham J.C. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47 (1998) 1326-1334
5. Chen Y.D., Sheu W.H., Swislocki A.L., and Reaven G.M. High density lipoprotein turnover in patients with hypertension. Hypertension 17 (1991) 386-393
6. Coimbra T.M., Janssen U., Grone H.J., Ostendorf T., Kunter U., Schmidt H., Brabant G., and Floege J. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int. 57 (2000) 167-182
7. Diep Q.N., Mabrouk M.E., Cohn J.S., Endemann D., Amiri F., Virdis A., Neves M.F., and Schiffrin E.L. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105 (2002) 2296-2302
8. Fujiwara K., Hayashi K., Ozawa Y., Tokuyama H., Nakamura A., and Saruta T. Renal protective effect of troglitazone in Wistar fatty rats. Metabolism 49 (2000) 1361-1364
9. Gaede P., Vedel P., Parving H.H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999) 617-622
10. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. 15 (2004) 2801-2815
11. Hayden M.R., Whaley-Connell A., and Sowers J.R. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am. J. Nephrol. 25 (2005) 553-569
12. Isshiki K., Haneda M., Koya D., Maeda S., Sugimoto T., and Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49 (2000) 1022-1032
13. Izzedine H., Launay-Vacher V., Buhaescu I., Heurtier A., Baumelou A., and Deray G. PPAR-gamma-agonists' renal effects. Minerva Urol. Nefrol. 57 (2005) 247-260
14. Janssen U., Phillips A.O., and Floege J. Rodent models of nephropathy associated with type II diabetes. J. Nephrol. 12 (1999) 159-172
15. Kasiske B.L., Cleary M.P., O'Donnell M.P., and Keane W.F. Effects of genetic obesity on renal structure and function in the Zucker rat. J. Lab. Clin. Med. 106 (1985) 598-604
16. Kasiske B.L., O'Donnell M.P., Cleary M.P., and Keane W.F. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 33 (1988) 667-672
17. Kasiske B.L., O'Donnell M.P., Cleary M.P., and Keane W.F. Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. Kidney Int. 35 (1989) 40-47
18. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27 (2004) 1496-1504
19. Kurosaki E., Momose K., Nakano R., Shimaya A., Suzuki T., Shibasaki M., and Shikama H. Hypoglycemic agent YM440 ameliorates the impaired hepatic glycogenesis after glucose loading by increasing glycogen synthase activity in obese Zucker rats. Jpn. J. Pharmacol. 89 (2002) 274-281
20. Kurosaki E., Nakano R., Shimaya A., Yoshida S., Ida M., Suzuki T., Shibasaki M., and Shikama H. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation. Biochem. Pharmacol. 65 (2003) 795-805
21. Kurosaki E., Nakano R., Momose K., Shimaya A., Suzuki T., Shibasaki M., and Shikama H. Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker rats. Eur. J. Pharmacol. 468 (2003) 151-158
22. Larsson L.I., Boder G.B., and Shaw W.N. Changes in the islets of langerhans in the obese Zucker rat. Lab. Invest. 36 (1977) 593-598
23. Nakano R., Kurosaki E., Shimaya A., Hirayama R., Shibasaki M., and Shikama H. Hypoglycemic agent, YM440 ameliorates the impaired sensitivity to insulin in regulating hepatic glucose output in obese Zucker rats. Diabetes 48 Suppl 1 (1999) A455-A456
24. Reaven G.M. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care 14 (1991) 195-202
25. Schmitz P.G., O'Donnell M.P., Kasiske B.L., Katz S.A., and Keane W.F. Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril. Am. J. Physiol. 263 3 Pt 2 (1992) F496-F502
26. Shibata T., Takeuchi S., Yokota S., Kakimoto K., Yonemori F., and Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br. J. Pharmacol. 130 (2000) 495-504
27. Shimaya A., Kurosaki E., Nakano R., Hirayama R., Shibasaki M., and Shikama H. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism 49 (2000) 411-417
28. Smith S.A., Lister C.A., Toseland C.D., and Buckingham R.E. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes. Metab. 2 (2000) 363-372
29. Stevenson F.T., and Kaysen G.A. Hyperlipidemia and renal disease: the use of animal models in understanding pathophysiology and approaches to treatment. Wien. Klin. Wochenschr. 111 (1999) 307-314
30. Tonolo G., Ciccarese M., Brizzi P., Puddu L., Secchi G., Calvia P., Atzeni M.M., Melis M.G., and Maioli M. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 20 (1997) 1891-1895
31. Yoshioka S., Nishino H., Shiraki T., Ikeda K., Koike H., Okuno A., Wada M., Fujiwara T., and Horikoshi H. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42 (1993) 75-80
32. Zhang Y., and Guan Y. PPAR-gamma agonists and diabetic nephropathy. Curr. Diab. Rep. 5 (2005) 470-475